Aptose Reports Annual and Special Shareholders Meeting Results

SAN DIEGO and TORONTO, June 18, 2024 – Aptose Biosciences Inc., a clinical-stage precision oncology firm focused on developing novel oral kinase inhibitors for hematologic cancers, has announced the outcomes of its annual and special meeting of shareholders. The meeting, held on June 18, 2024, saw participation from shareholders representing 49.67% of the company's common shares eligible to vote.

The company reported that all nominees listed in the proxy statement dated May 14, 2024, were successfully re-elected as directors. The voting results were as follows:

- Ms. Carol G. Ashe: 4,959,150 votes
- Dr. Denis Burger: 4,950,365 votes
- Dr. Erich Platzer: 4,963,215 votes
- Dr. William G. Rice: 4,331,196 votes
- Dr. Bernd Seizinger: 4,962,815 votes
- Dr. Mark D. Vincent: 4,963,303 votes
- Mr. Warren Whitehead: 4,951,313 votes

In addition to the board elections, shareholders approved several key matters:

1. The re-appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
2. An advisory resolution on the compensation of the corporation's named executive officers.
3. The potential issuance of common shares to warrant holders, exceeding 19.99% of the company's outstanding shares, according to Nasdaq Listing Rules.
4. A resolution permitting the adjournment of the meeting to solicit additional proxies if necessary.

Further details on these topics can be found in the company's proxy statement available on SEDAR+ and EDGAR. Final voting results will also be filed with these platforms.

Aptose Biosciences is dedicated to addressing unmet medical needs in oncology. Its pipeline includes small molecule cancer therapeutics designed to work as single agents or in combination with other treatments, without overlapping toxicities. The company is currently developing two oral kinase inhibitors for hematologic malignancies:

1. Tuspetinib (TUS) – An oral kinase inhibitor demonstrating effectiveness as both a monotherapy and in combination with other therapies for patients with relapsed or refractory acute myeloid leukemia (AML). It is being developed as a frontline triplet therapy for newly diagnosed AML.
2. Luxeptinib (CG-806) – An oral dual lymphoid and myeloid kinase inhibitor currently in Phase 1 a/b development for treating patients with relapsed or refractory hematologic malignancies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!